

CLAIM LISTING:

Claims 1-11 and 16-22 are canceled.

12. (Currently amended) A method of screening for a compound that modulates ~~CaCC~~ activity thereby affecting mucus secretion, the method comprising the steps of:

- a) contacting ~~CaCC, or fragment thereof,~~ hCLCA1 with the compound; and
- b) detecting ~~CaCC~~ hCLCA1 activity.

13. (Currently amended) The method of claim 12, wherein ~~CaCC~~ hCLCA1 is:

- a) expressed on a cell or tissue; or
- b) immobilized on a solid support.

14. (Currently amended) The method of claim 12, wherein the compound is:

- a) an antagonist of ~~CaCC~~ hCLCA1 activity; or
- b) an agonist of ~~CaCC~~ hCLCA1 activity.

23. (New) A method of screening for a compound that modulates mucin expression, said method comprising:

- a) contacting hCLCA1 with a compound; and
- b) detecting mucin expression or transcription.

24. (New) The method of claim 23, wherein mucin transcription is detected using RT-PCR.

25. (New) The method of claim 23, wherein mucin transcription is detected using a reporter gene operably linked to an hMUC2 promoter.